Xvivo was recently granted Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for the Xvivo Heart Preservation System (XHPS). We have talked to Christoffer Rosenblad, CFO, about the positive announcement, preparations for the upcoming clinical trials and other recent events in the transplant market.